Adult onset Still's disease—The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 2, 2017, Pages 295-302

  Junge, Guido ^a   Mason, June ^a   Feist, Eugen ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adult onset Still's disease; Anti interleukin 1 treatment; DMARD sparing; Steroid sparing

Indexed keywords

ANAKINRA; CANAKINUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RILONACEPT; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; INTERLEUKIN 1;

ADULT ONSET STILL DISEASE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; FOLLOW UP; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; HUMANS; INTERLEUKIN-1; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

EID: 85026220674     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.06.006     Document Type: Review

References (56)

1. Bywaters, E.G., Still's disease in the adult. Ann Rheum Dis 30 (1971), 121–133.
2. Hong, D., Yang, Z., Han, S., Liang, X., Ma, K., Zhang, X., Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Dev Ther 8 (2014), 2345–2357, 10.2147/DDDT.S73428.
3. Rudinskaya, A., Trock, D.H., Successful treatment of a patient with refractory adult-onset Still disease with anakinra. J Clin Rheumatol 9 (2003), 330–332, 10.1097/01.rhu.0000089966.48691.7f.
4. Haraoui, B., Bourrelle, D., Kaminska, E., Anakinra in the treatment of adult-onset Still's disease. Ann Rheum Dis 63 (2004), 293–294.
5. Aelion, J.A., Odhav, S.K., Prompt response to treatment with anakinra in Adult Onset Still's Disease. Ann Rheum Dis, 63, 2004, 293.
6. Godinho, F.M.V., Santos, M.J.P., da Silva, J.C., Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 64 (2005), 647–648, 10.1136/ard.2004.026617.
7. Debiais, S., Maillot, F., Luca, L., Buret, J., Fautrel, B., Renard, J.P., Efficacy of anakinra in a case of refractory Still disease. J Clin Rheumatol 14 (2008), 357–358, 10.1097/RHU.0b013e318188b8d8.
8. Mylona, E., Golfinopoulou, S., Samarkos, M., Fanourgiakis, P., Papadakos, V., Skoutelis, A., Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra. Clin Rheumatol 27 (2008), 659–661, 10.1007/s10067-007-0791-y.
9. El Karoui, K., Karras, A., Lebrun, G., Charles, P., Arlet, J.B., Jacquot, C., et al. Thrombotic microangiopathy and Purtscher-like retinopathy associated with adult-onset Still's disease: a role for glomerular vascular endothelial growth factor?. Arthritis Rheum 61 (2009), 1609–1613, 10.1002/art.24826.
10. Gesierich, A., Stoevesandt, J., Kneitz, C., Brocker, E.B., Schon, M.P., Adult-onset Still's disease: an uncommon differential diagnosis of urticaria and treatment with anakinra. J Eur Acad Dermatol Venereol 23 (2009), 104–106, 10.1111/j.1468-3083.2008.02746.x.
11. Sentic, M., Baresic, M., Anic, B., Bosnic, D., Mayer, M., Cerovec, M., et al. Treatment challenges in patient with refractory adult Still's disease—a case report. Clin Exp Rheumatol 27 (2009), 733–734.
12. Moulis, G., Sailler, L., Astudillo, L., Pugnet, G., Arlet, P., May anakinra be used earlier in adult onset Still disease?. Clin Rheumatol 29 (2010), 1199–1200, 10.1007/s10067-010-1459-6.
13. Lahiri, M., Teng, G.G., A case of refractory adult-onset Still's disease treated with anakinra. Int J Rheum Dis 13 (2010), e36–e41.
14. Tamaki, H., Shimizu, H., Hiraoka, E., Uechi, E., Kishimoto, M., Yamaguchi, K., et al. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease. Mod Rheumatol 20 (2010), 200–204, 10.1007/s10165-009-0254-1.
15. Raffeiner, B., Botsios, C., Dinarello, C., Ometto, F., Punzi, L., Ramonda, R., Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine 78 (2011), 100–101, 10.1016/j.jbspin.2010.09.014.
16. Brusch, A., Hollingsworth, P., Mclean-Tooke, A., Successful treatment of refractory adult onset Still's disease with anakinra. Intern Med J 41 (2011), 2–3.
17. Banse, C., Vittecoq, O., Benhamou, Y., Gauthier-Prieur, M., Lequerre, T., Levesque, H., Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine 80 (2013), 653–655, 10.1016/j.jbspin.2013.04.011.
18. Gutmark, R., Eliasieh, K., Rivera-Michlig, R., A case of bilateral trochleitis in adult-onset Still׳s disease. Semin Arthritis Rheum 43 (2014), 689–691, 10.1016/j.semarthrit.2013.09.003.
19. Luconi, N., Risse, J., Busato, T., Galland, J., Mandry, D., Voilliot, D., et al. Myocarditis in a young man with adult onset Still's disease successfully treated with Il-1 blocker. Int J Cardiol 189 (2015), 220–222, 10.1016/j.ijcard.2015.04.071.
20. Waghmare, S., Valecka, B., Cairns, A.P., A severe case of adult onset Stills disease with myopericarditis, resistant to treatment with tocilizumab but responsive to anakinra. Ulster Med J 84 (2015), 130–132.
21. Fitzgerald, A.A., Leclercq, S.A., Yan, A., Homik, J.E., Dinarello, C.A., Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52 (2005), 1794–1803, 10.1002/art.21061.
22. Chu, C.Q., Hughes, G., Karr, N., Gardner, G., Interleukin-1 blockade is an effective treatment of adult onset Still's disease. Arthritis Rheum, 52, 2005, 4101.
23. Kalliolias, G.D., Georgiou, P.E., Antonopoulos, I.A., Andonopoulos, A.P., Liossis, S.N.C., Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66 (2007), 842–843, 10.1136/ard.2006.066381.
24. Kötter, I., Wacker, A., Koch, S., Henes, J., Richter, C., Engel, A., et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheu 37 (2007), 189–197, 10.1016/j.semarthrit.2007.04.002.
25. Naumann, L., Feist, E., Natusch, A., Langen, S., Krause, A., Buttgereit, F., et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 69 (2010), 466–467, 10.1136/ard.2009.108068.
26. Franchini, S., Dagna, L., Salvo, F., Aiello, P., Baldissera, E., Sabbadini, M.G., Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 62 (2010), 2530–2535, 10.1002/art.27532.
27. Laskari, K., Tzioufas, A.G., Moutsopoulos, H.M., Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther, 13, 2011, R91, 10.1186/ar3366.
28. Jaqua, N.T., Finger, D., Hawley, J.S., Adult-onset Still's disease masquerading as sepsis in an asplenic active duty soldier. Case Rep Med, 2012, 2012, 349521, 10.1155/2012/349521.
29. Cavalli, G., Franchini, S., Berti, A., Campochiaro, C., Guglielmi, B., Sabbadini, M.G., et al. Efficacy and safety of biologic agents in adult-onset Still's disease: a long-term follow-up of 19 patients at a single referral center. Arthritis Rheum, 65(Suppl. 10), 2013, 2028, 10.1002/art.2013.65.issue-s10.
30. Cavalli, G., Franchini, S., Aiello, P., Guglielmi, B., Berti, A., Campochiaro, C., et al. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol 44 (2015), 309–314, 10.3109/03009742.2014.992949.
31. Iliou, C., Papagoras, C., Tsifetaki, N., Voulgari, P.V., Drosos, A.A., Adult-onset Still's disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol 31 (2013), 47–52.
32. Maria, A.T., Le Quellec, A., Jorgensen, C., Touitou, I., Riviere, S., Guilpain, P., Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13 (2014), 1149–1159, 10.1016/j.autrev.2014.08.032.
33. Gerfaud-Valentin, M., Maucort-Boulch, D., Hot, A., Iwaz, J., Ninet, J., Durieu, I., et al. Adult-onset still disease manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine 93 (2014), 91–99, 10.1097/Md.0000000000000021.
34. Nordstrom, D., Knight, A., Luukkainen, R., van Vollenhoven, R., Rantalaiho, V., Kajalainen, A., et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 39 (2012), 2008–2011, 10.3899/jrheum.111549.
35. Lequerre, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008), 302–308, 10.1136/ard.2007.076034.
36. Giampietro, C., Ridene, M., Fautrel, B., Bourgeois, P., Long term treatment with anakinra in patients with adult-onset Still's disease. Arthritis Rheum, 10, 2010, S373.
37. Giampietro, C., Ridene, M., Lequerre, T., Chalumeau, N.C., Amoura, Z., Sellam, J., et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthrit Care Res 65 (2013), 822–826, 10.1002/acr.21901.
38. Rossi-Semerano, L., Fautrel, B., Wendling, D., Hachulla, E., Galeotti, C., Semerano, L., et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis, 2015, 10, 10.1186/s13023-015-0228-7.
39. Ortiz-Sanjuan, F., Blanco, R., Riancho-Zarrabeitia, L., Castaneda, S., Olive, A., Riveros, A., et al. Efficacy of anakinra in refractory adult-onset Still's disease multicenter study of 41 patients and literature review. Medicine, 94, 2015, 10.1097/MD.0000000000001554.
40. Kontzias, A., Efthimiou, P., The use of canakinumab, a novel IL-1 beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheu 42 (2012), 201–205, 10.1016/j.semarthrit.2012.03.004.
41. Barsotti, S., Neri, R., Iacopetti, V., d׳Ascanio, A., Talarico, R., Tripoli, A., et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol, 20, 2014, 121, 10.1097/rhu.0000000000000082.
42. Goldbach-Mansky, R., Snyder, C., Pham, T., Barham, B., Kastner, D., Papandoupulos, J., et al. Differential response to the long acting IL-1 inhibitor IL-1 trap in 2 patients with Adult Onset Still's Disease (AOSD). Ann Rheum Dis, 65, 2006, 262.
43. Petryna, O., Cush, J.J., Efthimiou, P., IL-1 trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis 71 (2012), 2056–2057, 10.1136/annrheumdis-2012-201409.
44. Henderson, C., Wilson, M., Pham, T.-H., Dolan, G., Gobbo, A., Snyder, C., et al. Safety and efficacy of IL-1 trap in resistant adult onset Still's disease: 24 month follow-up of open label treatment and biomarkers of response. Arthritis Rheum, 62, 2010, 1831, 10.1002/art.29596.
45. Eriksson, P., Jacobs, C., Soderkvist, P., A patient with a phenotype of adult-onset still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. J Rheumatol 40 (2013), 1632–1633, 10.3899/jrheum.130325.
46. Lo Gullo, A., Caruso, A., Pipitone, N., Macchioni, P., Pazzola, G., Salvarani, C., Canakinumab in a case of adult onset Still's disease: efficacy only on systemic manifestations. Joint Bone Spine 81 (2014), 376–377, 10.1016/j.jbspin.2013.12.011.
47. Athanassiou, P., Basdragianni, D., Tzanavari, A., Thantafyllidou, E., Kostoglou-Athanassiou, I., Adult Still's disease: successful treatment with canakinumab. Osteoporos Int, 25, 2014, S424.
48. Pay, S., Turkcapar, N., Kalyoncu, M., Simsek, I., Beyan, E., Ertenli, I., et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 25 (2006), 639–644, 10.1007/s10067-005-0138-5.
49. Fautrel, B., Borget, C., Rozenberg, S., Meyer, O., Le Loet, X., Masson, C., et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26 (1999), 373–378.
50. Brachat, A., Grom, A., Wulffraat, N., Brunner, H., Quartier, P., Brik, R., et al. OP0007 Changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Ann Rheum Dis, 73(Suppl. 2), 2014, 62, 10.1136/annrheumdis-2014-eular.2320.
51. Nirmala, N., Brachat, A., Feist, E., Blank, N., Specker, C., Witt, M., et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J, 13, 2015, 50, 10.1186/s12969-015-0047-3.
52. Castañeda, S., Blanco, R., González-Gay, M.A., Adult-onset Still's disease: advances in the treatment. Best Pract Res Clin Rheumatol 30 (2016), 222–238, 10.1016/j.berh.2016.08.003.
53. Ortiz-Sanjuán, F., Blanco, R., Calvo-Rio, V., Narvaez, J., Rubio Romero, E., Olivé, A., et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66 (2014), 1659–1665, 10.1002/art.38398.
54. Pouchot, J., Arlet, J.B., Biological treatment in adult-onset Still's disease. Best Pract Res Clin Rheumatol 26 (2012), 477–487, 10.1016/j.berh.2012.07.002.
55. Nigrovic, P.A., Mannion, M., Prince, F.H., Zeft, A., Rabinovich, C.E., van Rossum, M.A., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63 (2011), 545–555, 10.1002/art.30128.
56. Vastert, S.J., de Jager, W., Noordman, B.J., Holzinger, D., Kuis, W., Prakken, B.J., et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66 (2014), 1034–1043, 10.1002/art.38296.